Gene and Cell Therapy: Quality Developments to Commercialization Summit
05-06

June 2019

Berlin

Germany

About

We are pleased to invite you to the Annual Gene and Cell Therapy: Quality Developments to Commercialization Summit, scheduled for June 5 - 6, 2019 in Berlin, Germany. This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers, while facilitating a professional atmosphere and environment for good company representation and development. The summit will shed light on the delivery of cost and quality efficient process development, manufacturing, and commercialization of cell and gene therapies. It is...

We are pleased to invite you to the Annual Gene and Cell Therapy: Quality Developments to Commercialization Summit, scheduled for June 5 - 6, 2019 in Berlin, Germany. This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers, while facilitating a professional atmosphere and environment for good company representation and development. The summit will shed light on the delivery of cost and quality efficient process development, manufacturing, and commercialization of cell and gene therapies. It is an honour and privilege to invite you to participate in this Summit. We look forward to welcoming you in Berlin in June!

more info
Who Should Attend

Chief Executives, Vice Presidents, Directors, Heads, Leaders, and Managers specialising in:

  • Advanced Therapy Production
  • Bioprocessing
  • CAR-T
  • Cell Therapy
  • Cellular Therapy
  • CMC
  • GMP
  • Immune Deficiencies
  • Immunology
  • Immunotherapy
  • Manufacturing
  • Medical
  • Precision Medicine
  • Process Development
  • R&D
  • Regulatory
  • Stem Cell
  • Tissue Therapy
  • Analytical
  • Biotherapeutics
  • Cell Engineering
  • Cellular Immunotherapy
  • Clinical Development
  • Gene Therapy
  • Health Economics
  • Immuno-Oncology
  • Immunology Chemistry
  • Legal/IP
  • Market Access
  • Oncology
  • Pricing
  • Quality Control
  • Regenerative Medicine
  • Sales
  • Supply Chain
Key Practical Learning Points of the Summit

Optimized cell and gene therapies process development, manufacturing, cost, and quality efficiency
Emerging science and technologies to enhance cell and gene therapies development
Advanced analytical approaches to improve quality control and real-time release
Regulatory compliance to empower development and commercialization strategies of cell and gene therapies
Robust supply chain design for precision medicine therapies
Speakers
Stephan Reynier, FR

Chief Regulatory & Compliance Officer

Cellectis

Christine Le Bec, FR

Upstream Process Development Supervisor

Genethon

Dr. Manuela Cota, IT

Upstream Process Development Supervisor

MolMed

Dr. Kathryn Parsley, UK

Associate Director, Regulatory Affairs

Boyd Consultants

Marian Bendik, AT

Site Lead Orth for Gene Therapy Center Austria

Takeda

Dr. Vladimir Slepushkin, US

Director of Vector R&D

Kite Pharma, a Gilead Company

Dr. Basel Assaf, US

Sr. Principal Scientist

Pfizer

Dr. Jacek Lubelski, US

VP, Global Pharmaceutical Development

uniQure

E.J. Brandreth, US

Head of Quality

Inovio Pharmaceuticals

Dr. Paul Byrne, UK

Lead Scientist, Cell & Gene Therapy Biopharmaceutical CMC Solutions

Covance

Catherine Cancian, FR

VP, Pharmaceutical Operations

GenSight Biologics

Lior Raviv, IL

Vice President of Development

Pluristem

Dr. Rita Majithiya, UK

Scientific Leader, Formulation Development,Cell & Gene Therapy

GSK

Dr. Axel Ståhlbom, SE

Principal Consultant Biologics & Preclinicical

ProPharma Group

Dr. Carmen Brenner, BE

QC Associate Director

Bone Therapeutics

"